ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1780

Pulmonary Disease in Late Versus Early Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis

Jennifer Medlin1, Karen Hansen2, Sara McCoy3 and Christie M. Bartels4, 1Internal Medicine, University of Wisconsin Hospitals and Clinics, Madison, WI, 2Department of Medicine, Division of Rheumatology, University of Wisconsin School of Medicine and Public Health, Madison, WI, 3Department of Medicine, Rheumatology Division, University of Wisconsin School of Medicine and Public Health, Madison, WI, 4Medicine, Rheumatology, University of Wisconsin School of Medicine and Public Health, Madison, WI

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: interstitial lung disease, meta-analysis, pulmonary complications and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Phenotypes often differ in late-onset systemic lupus erythematosus (SLE) compared to SLE features in early-onset patients. Prior studies have suggested that there may be more pulmonary disease in the older onset population. This systematic review and meta-analysis evaluates the differences in pulmonary manifestations between late and early-onset SLE.

Methods: We searched the literature using PubMed, CINAHL, Web of Science and Cochrane Library. We excluded studies that did not include ACR SLE classification criteria, lacked early-onset controls, defined late-onset SLE as <50 years of age, or were not written in English. Two authors rated study quality using the Newcastle Ottawa Quality Scale. We used random effects models to create Forest plots to compare odds ratios and 95% confidence intervals of pulmonary manifestations by onset age. We specifically assessed interstitial lung disease, serositis, pleuritis, pulmonary embolism, pulmonary hypertension, or a composite of any lung disease. We assessed heterogeneity using I2.

Results: Thirty six studies, representing 10,504 early-onset and 1,529 late-onset patients with SLE, met eligibility criteria. The prevalence of pulmonary manifestations was higher in the late-onset group as shown in Table 1. Interstitial lung disease (ILD) was nearly three times as common (OR 2.56 (1.27, 5.16)) with low study heterogeneity (I2 23%, p=0.23). Pleuritis (OR 1.53 (1.19, 1.96)) and serositis (OR 1.24 (1.03, 1.51)) were also more common in the late-onset group for which there was low to moderate heterogeneity (I2 36%, p=0.07 and I2 43%, p=0.005). The mean Newcastle Ottawa Quality Scale score for study quality was 6.9 ±0.7 (scale 0-9).

Conclusion:   Pulmonary manifestations of SLE appear to be more common in late-onset SLE patients compared to their younger peers, particularly ILD.  Age-related changes of the immune system, tobacco and antigen exposure history, race, and possible association with Sjogren’s syndrome are possible contributors that should be examined in future studies.  


Disclosure: J. Medlin, None; K. Hansen, None; S. McCoy, None; C. M. Bartels, None.

To cite this abstract in AMA style:

Medlin J, Hansen K, McCoy S, Bartels CM. Pulmonary Disease in Late Versus Early Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/pulmonary-disease-in-late-versus-early-systemic-lupus-erythematosus-a-systematic-review-and-meta-analysis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pulmonary-disease-in-late-versus-early-systemic-lupus-erythematosus-a-systematic-review-and-meta-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology